Keywords
Abstract
Maqolada qon ivish tizimining genetik asoslari va ularning tromboz rivojlanishidagi roli ilmiy asosda tahlil qilinadi. Xususan, FVL (Leiden mutatsiyasi), protrombin G20210A, MTHFR, va boshqa genetik polimorfizmlarning tromboz xavfiga ta’siri yoritiladi. Zamonaviy genetik skrining usullarining tromboz profilaktikasida qo‘llanilishi, shuningdek, individual xavfni baholash va shaxsiylashtirilgan davolash strategiyalariga olib keluvchi yo‘nalishlar muhokama qilinadi. Maqola klinik amaliyotda genetik testlarning afzalliklari va cheklovlarini ham yoritib beradi.
References
1. Kujovich, J.L. (2011). Factor V Leiden thrombophilia. Genetics in Medicine, 13(1), 1–16.
2. Poort, S.R., Rosendaal, F.R., Reitsma, P.H., Bertina, R.M. (1996). A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increased risk of venous thrombosis. Blood, 88(10), 3698–3703.
3. den Heijer, M., Lewington, S., Clarke, R. (2005). Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. Journal of Thrombosis and Haemostasis, 3(2), 292–299.
4. Duga, S., Asselta, R. (2019). Genetic risk factors for venous thromboembolism: current knowledge and future challenges. Journal of Translational Medicine, 17, Article 266.
5. Reitsma, P.H., Versteeg, H.H., Middeldorp, S. (2012). Mechanistic view of risk factors for venous thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(3), 563–568.
6. Kujovich, J.L. (2009). Thrombophilia and pregnancy complications. American Journal of Obstetrics and Gynecology, 201(4), 327.e1–327.e13.
7. Martinelli, I., Bucciarelli, P., Mannucci, P.M. (2010). Thrombotic risk factors: basic pathophysiology. Critical Care Medicine, 38(2 Suppl), S3–S9.
8. Kearon, C., et al. (2016). Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest, 149(2), 315–352.